Jacobs Engineering (JEC) Selected to Provide Design, Engineering Services for Pfizer's Global Biotech Center in China
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Jacobs Engineering Group Inc. (NYSE: JEC) announced it was awarded a contract to lead design and provide engineering services, procurement and construction support for Pfizer, Inc.’s new $350 million Global Biotechnology Center investment in the Hangzhou Economic Development Area in China.
Under the terms of the agreement, Jacobs is responsible for developing the overall site design, which includes aseptic fill/finish, drug substance and central utility buildings; a quality laboratory; administration offices; and a warehouse. The facility is being built to produce monoclonal antibodies and also serve as a process development and clinical supply site for biologic medicines in China.
In making the announcement, Jacobs Senior Vice President Life Sciences Robert Norfleet stated, “This is an exciting opportunity for our Life Sciences business. We have a long history of helping Pfizer grow and expand its global manufacturing capabilities. We look forward to partnering with Pfizer once again to develop this state-of-the-art biotechnology center in China.”
The facility is expected to be complete in 2018.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jacobs Engineering (JEC) Plans to Initiate Dividend with Target Yield of 1%
- Teva Pharma (TEVA) Loses Bid to Revive '413, '250, and Third Capaxone Patent in IPR Review - Bloomberg
- Johnson & Johnson (JNJ) Receives Adverse Decision in Texas Hip Implants Case; Will Pay $1B
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!